Production and characterization of a genetically engineered anti-caffeine camelid antibody and its use in immunoaffinity chromatography

被引:26
|
作者
Franco, Elliott J. [1 ]
Sonneson, Gregory J. [1 ]
DeLegge, Thomas J. [1 ]
Hofstetter, Heike [1 ]
Horn, James R. [1 ]
Hofstetter, Oliver [1 ]
机构
[1] No Illinois Univ, Dept Chem & Biochem, De Kalb, IL 60115 USA
关键词
Caffeine; Camelid antibody; CDR grafting; Immunoaffinity chromatography; Small molecule; VHH; SINGLE-DOMAIN ANTIBODY; AFFINITY; PERFORMANCE; IMMOBILIZATION; SEPARATION; FRAGMENTS; PROTEINS; ENANTIOMERS; STABILITY; DIGESTION;
D O I
10.1016/j.jchromb.2009.06.017
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This work demonstrates the feasibility of using a camelid single domain antibody for immunoaffinity chromatographic seperation of small molecules An anti-caffeine VHH antibody was produced by grafting the complementanty determining sequences of a previously generated antibody onto an anti-RNase A antibody scaffold. followed by expression in E colt. Analysis of the binding properties of the antibody by ELISA and fluorescence-based thermal shift assays showed that it recognizes not only caffeine, but also theophylline. theobiomine. and paraxanthine, albeit with lower affinity Further investigation of the effect of environmental conditions. I e, temperature, pH. and ionic strength, on the antibody using these methods provided useful information about potential elation conditions to be used in chromatographic applications. Immobilization of the VHH onto a high flow-through synthetic support material resulted In a stationary phase capable of separating caffeine and its metabolites (C) 2009 Elsevier B.V. All rights reserved
引用
收藏
页码:177 / 186
页数:10
相关论文
共 34 条
  • [31] Expression and characterization of an anti-(hepatitis B surface antigen) glycosylated mouse antibody in transgenic tobacco (Nicotiana tabacum) plants and its use in the immunopurification of its target antigen
    Ramírez, N
    Rodríguez, M
    Ayala, M
    Cremata, J
    Pérez, M
    Martínez, A
    Linares, M
    Hevia, Y
    Páez, R
    Valdés, R
    Gavilondo, JV
    Selman-Housein, G
    BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2003, 38 (03) : 223 - 230
  • [32] Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
    Stein, R
    Qu, ZX
    Chen, S
    Rosario, A
    Shi, V
    Hayes, M
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2868 - 2878
  • [33] Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use
    Tsuda, Eisuke
    Fukuda, Chie
    Okada, Akiko
    Karibe, Tsuyoshi
    Hiruma, Yoshiharu
    Takagi, Nana
    Isumi, Yoshitaka
    Yamamoto, Tomomaya
    Hasegawa, Tomoka
    Uehara, Shunsuke
    Koide, Masanori
    Udagawa, Nobuyuki
    Amizuka, Norio
    Kumakura, Seiichiro
    BONE, 2022, 155
  • [34] CHARACTERIZATION OF A MONOCLONAL RAT ANTI-MOUSE INTERLEUKIN-2 (IL-2) RECEPTOR ANTIBODY AND ITS USE IN THE BIOCHEMICAL-CHARACTERIZATION OF THE MURINE IL-2 RECEPTOR
    GAULTON, GN
    BANGS, J
    MADDOCK, S
    SPRINGER, T
    EARDLEY, DD
    STROM, TB
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1985, 36 (01): : 18 - 29